[Edaily Reporter Park Jung-Soo ] E-Su Group announced on the 24th that it held the “2026 Integrated IR Day” on the 18th to share the first-half business results of its major affiliates and future growth strategies.
Participating in this IR Day were IsuChemical(005950), ISUPETASYS(007660), ISU SPECIALTY CHEMICAL, and ISU Abxis Co., Ltd.(086890), which presented their first-half results and the status of key businesses, as well as medium- to long-term strategies encompassing future growth sectors such as artificial intelligence (AI), batteries, and biotechnology.
Celebrating its 30th anniversary this year, the Isu Group plans to expand its future growth engines by leveraging the competitiveness of its existing businesses. Building on the stable business foundation of IsuChemical, the group will foster ISUPETASYS’s high-performance AI hardware, ISU SPECIALTY CHEMICAL’s battery materials, and ISU Abxis Co., Ltd.’s bio and healthcare businesses as key growth pillars.
ISUPETASYS posted record-high second-quarter earnings, driven by expanded investments in AI data centers by global Big Tech companies. Consolidated revenue reached 379.9 billion won, a 57% increase year-over-year, while operating profit rose 83% to 77.1 billion won. The operating profit margin stood at 20.3%. As of the end of the second quarter, the standalone order backlog totaled 622.2 billion won.
The expansion of high-margin products, such as AI accelerators and 800G-class switches, drove these results. ISUPETASYS is expanding its lineup of next-generation 800G and 1.6T switches, as well as its Multi-Lam and HDI product lines, while pursuing joint development and mass production with global clients.
The company is also continuing to invest in expanding production capacity. By adding additional investment to its existing mid-to-long-term expansion plan worth 400 billion won, it will construct manufacturing facilities and ancillary infrastructure for Plant No. 6, as well as production facilities for high-specification printed circuit boards (PCBs). The company projects that, if investments proceed as planned, its production capacity (CAPA) based on annual revenue will exceed 2 trillion won by 2028.
IsuChemical posted its best-ever half-year results, with consolidated revenue of 1.3793 trillion won and operating profit of 122 billion won for the first half of the year. On a standalone basis for the chemicals division, second-quarter revenue was 643.5 billion won, and operating profit was 91.6 billion won. The company explained that these results were driven by enhanced cost competitiveness and improved spreads achieved through vertical integration of normal paraffin (NP) and liquid alkylbenzene (LAB).
In terms of new business initiatives, the company is developing synthetic oil-based immersion cooling fluids to meet the growing demand for high-density, high-power racks in AI data centers. It is also expanding its business scope into high-value-added products such as specialty insulating oils. In partnership with U.S. engineering firm KBR, the company has signed a Memorandum of Understanding (MOU) to construct an ammonia cracking facility at its Onsan plant with a daily production capacity of 10 metric tons for hydrogen production.
ISU SPECIALTY CHEMICAL posted second-quarter revenue of 108 billion won and operating profit of 7.7 billion won. Cumulative revenue for the first half of the year totaled 216.6 billion won, with operating profit reaching 11.2 billion won.
The company is also preparing to commercialize its lithium sulfide (Li₂S) business, a key material for all-solid-state batteries. It completed the early construction of its lithium sulfide mother plant last June and is currently conducting trial operations with the goal of achieving full-scale operation in the second half of the year. It is also conducting quality tests and supply discussions with domestic and international battery cell and original equipment manufacturer (OEM) companies.
ISU Abxis Co., Ltd. is expanding its pipeline of next-generation antibody drugs while continuing its existing product businesses, including Absertin, Pavagal, and Clotinap. Following the Opdivo biosimilar and anti-HER3 antibody, the company is broadening its R&D scope into the field of bispecific antibodies—such as PD-1×targets and VEGF×targets—and is also pursuing the discovery of new drug candidates using AI.
The E-Su Group aims to achieve 6 trillion won in revenue and 600 billion won in operating profit by 2030 through the expansion of growth businesses across its affiliates.